These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36314778)

  • 1. Impact of saline infusion and citrate infusion rate during donor plasmapheresis.
    Evers J; Schreiber GB; Taborski U
    J Clin Apher; 2022 Dec; 37(6):584-591. PubMed ID: 36314778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of citrate and citrate infusion rate during donor plasmaphereses.
    Evers J; Taborski U
    J Clin Apher; 2016 Feb; 31(1):59-62. PubMed ID: 26011445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis.
    Buzza M; Marks DC; Capper H; Cassin E; Badcock CA; Reid S; Kwok M; Yang H; Lee J; Corrigan C; Hartkopf-Theis T; Keller A
    Transfusion; 2012 Aug; 52(8):1806-13. PubMed ID: 22348664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin G levels during collection of large volume plasma for fractionation.
    Burkhardt T; Rothe R; Moog R
    Transfus Apher Sci; 2017 Jun; 56(3):417-420. PubMed ID: 28454884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of saline infusion as replacement fluid at donor plasmapheresis.
    Evers J; Schreiber GB; Taborski U
    J Clin Apher; 2022 Dec; 37(6):611-612. PubMed ID: 36123808
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum content of source plasma and sodium citrate anticoagulant.
    May JC; Rains TC; Yu LJ; Etz NM
    Vox Sang; 1992; 62(2):65-9. PubMed ID: 1519369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective trial on the safety of long-term intensive plasmapheresis in donors.
    Bechtloff S; Tran-My B; Haubelt H; Stelzer G; Anders C; Hellstern P
    Vox Sang; 2005 Apr; 88(3):189-95. PubMed ID: 15787729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Short-term effects of citrate on markers of bone metabolism in Chinese blood donor volunteers].
    Chu XL; Hou JM; Lin H; Lin HK; Zeng J; Chen GL; Chen C; Lin J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):785-9. PubMed ID: 20561451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation, bleeding, and clotting at donor plasmapheresis.
    Evers J; Taborski U
    J Clin Apher; 2018 Aug; 33(4):538-540. PubMed ID: 29575131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor safety in an individualized plasmapheresis program - Results of an interim analysis.
    Taborski U; Laitinen T
    Transfus Apher Sci; 2022 Oct; 61(5):103446. PubMed ID: 35461780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report on 50 cases of severe acute hypotension at donor plasmaphereses: treatment and course.
    Evers J; Schreiber GB; Taborski U
    Int J Artif Organs; 2017 May; 40(5):230-233. PubMed ID: 28525673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA).
    Schulzki T; Seidel K; Storch H; Karges H; Kiessig S; Schneider S; Taborski U; Wolter K; Steppat D; Behm E; Zeisner M; Hellstern P;
    Vox Sang; 2006 Aug; 91(2):162-73. PubMed ID: 16907878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of NaCl 0.9% Infusion during Plasmapheresis on IgG Content in Plasma.
    Evers J; Betz J; Blankenburg T; Engelen T; Galle G; Hansen M; Laitinen T; Taborski U
    Transfus Med Hemother; 2010; 37(4):191-194. PubMed ID: 21048825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
    Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
    Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the intensity of serial automated plasmapheresis and the speed of deep-freezing on the quality of plasma.
    Hellstern P; Bach J; Haubelt H; Hitzler WE; Mathis S; Vogt A
    Transfusion; 2001 Dec; 41(12):1601-5. PubMed ID: 11778078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IgG and IgM levels in new and regular long-term plasmapheresis donors.
    Burgin M; Hopkins G; Moore B; Nasser J; Richardson A; Minchinton R
    Med Lab Sci; 1992 Dec; 49(4):265-70. PubMed ID: 1339930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization.
    Mohammadi S; Aghabozorg F; Balagholi S; Ferdowsi S; Sharifi S; Eshghi P
    Int J Hematol Oncol Stem Cell Res; 2022 Jul; 16(3):151-156. PubMed ID: 36694705
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of plasmapheresis on blood pressure in voluntary plasma donors.
    Rosa-Bray M; Wisdom C; Marier JF; Mouksassi MS; Wada S
    Vox Sang; 2015 Jan; 108(1):11-7. PubMed ID: 25169580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events.
    Thijsen A; Davison TE; Speedy J; Hoad V; Masser B
    Vox Sang; 2021 Mar; 116(3):273-280. PubMed ID: 32702163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.